In this regard Novo Nordisk is leading the way. We've become increasingly committed to chronic conditions that include cardiovascular disease and chronic kidney disease – the reason being ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

A spirited pro/con debate at ERA 2025 explores whether population-level albuminuria screening could improve early CKD detection, with feasibility, cost-effectiveness, and equity all weighed.

Sending letters to encourage guideline-directed practice in the management of chronic kidney disease to either patients or their general practitioner does not improve prescription rates, shows trial.

An international clinical trial, led in the UK by Swansea’s Joint Clinical Research Facility (JCRF), has found that ...

Doctors and researchers are exploring various approaches to tackle this pervasive health issue, from new medications to dietary interventions. But what if one of the most promising treatments relies ...

Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...

A new genetic study on the causes of chronic kidney disease that combined multiple health measurements has led to a more ...

Yale School of Medicine researchers have identified a biomarker panel that improves the assessment of chronic kidney disease ...